PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
Sign Up to like & getrecommendations! Published in 2017 at "World Journal of Urology"
DOI: 10.1007/s00345-017-2138-x
Abstract: PurposeTo evaluate the association between prostate-specific antigen (PSA) response and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel.MethodsMen with mCRPC receiving cabazitaxel (25 mg/m2, every 3 weeks) plus oral prednis(ol)one… read more here.
Keywords: free survival; psa response; progression free; survival ... See more keywords
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12051078
Abstract: Lutetium-177-PSMA ([177Lu]-PSMA-617), a radiolabeled small molecule, binds with high affinity to prostate-specific membrane antigen (PSMA), enabling targeted radiation therapy to metastatic prostate lesions. Our objective was to retrospectively analyze the activity of [177Lu]-PSMA-617 given off-trial… read more here.
Keywords: psma 617; 177lu psma; associated psa; psa response ... See more keywords